Featured · Apr 27

Available now: The 147 Global Opinion Leaders in Lupus

The global market for drugs to treat Systematic lupus erythematosus (SLE) is predicted to see a compound annual growth of 22.4% between now and 2018. SLE is a therapy area long marked by unmet medical need, and finding the right …

Read more

Apr 17

The art and science of local KOLs

Marketers can stay ahead of the curve with regional knowledge Looking at a slide from a recent AstraZeneca investor presentation on segmenting patient subsets in severe asthma, I was struck anew by the rate at which the industry is moving …

Read more

Apr 17

Mapping KOL relationships

Network maps can deliver a wealth of information In last month’s article, we established the value of getting to know individual key opinion leaders (KOLs) and their needs, beliefs and aspirations. This month, we look at how mapping the KOL …

Read more

Apr 17

Sustaining relationships

Do you really understand the KOLs you work with? You don’t need to be told about the importance of working with KOLs or external medical experts, nor that you are in competition for their time and attention. But how well …

Read more

Dec 10

Why pharma must rethink KOL strategy for emerging markets

Kendle Healthcare has done some work recently on identifying important stakeholders in emerging markets. These projects got me thinking about how the likes of India, Brazil, China and other BRIC-MT countries are representative of an ever-evolving KOL landscape, particularly with …

Read more